Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
409 Ergebnisse für "discovered" unter Somagenetix
Missed clinical clues in patients with pheochromocytoma/paraganglio...
... potential differences in clinical presentation between PPGLs discovered by imaging (iPPGLs), symptomatic ... . Précis: Pheochromocytoma/paraganglioma discovered by imaging are often symptomatic and carry a ... Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging ... Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging ... Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging ...
Microviridin 1777: A Toxic Chymotrypsin Inhibitor Discovered by a M...
... Microviridin 1777: A Toxic Chymotrypsin Inhibitor Discovered by a Metabologenomic Approach - Zurich ... Microviridin 1777: A Toxic Chymotrypsin Inhibitor Discovered by a Metabologenomic Approach - Zurich ... Microviridin 1777: A Toxic Chymotrypsin Inhibitor Discovered by a Metabologenomic Approach - Zurich ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
246 Ergebnisse für "discovered" unter University of Zurich
UZH - Chair for Marketing and Market Research - Dr. Xin-Yu Zou
... discovered; the point is to discover them.” Galileo Galilei New product pre-announcement Politecnico di ... they are discovered; the point is to discover them.” Galileo Galilei Description Xin-Yu is a PhD ...
UZH - Institute of Experimental Immunology
... Ducimetière, Lucchiari at al discovered that hepatic innate lymphocytes cooperate in a non-redundant fashion ... disseminated cancer cells that have become dormant. Paulino Tallón de Lara, Héctor Castañón et al. discovered ... , Lucchiari at al discovered that hepatic innate lymphocytes cooperate in a non-redundant fashion to control ... cancer cells that have become dormant. Paulino Tallón de Lara, Héctor Castañón et al. discovered that ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
326 Ergebnisse für "discovered" unter ETH Entrepreneurship
News – Page 4 – ZISC
... in background to record all touchscreen input system-wide. By using the newly discovered attack, a ... newly discovered attack, a malicious application running on the system is able to profile user’s ...
Paper published – Soft and Living Materials | ETH Zurich
... , have recently discovered the first three dimensional photonic crystals made from protein. 20.05.2021 ... discovered the first three dimensional photonic crystals made from protein in the feather barbs of blue ... Eric’s long-time collaborators Vinod Saranathan and Richard Prum, have recently discovered the first ... Richard Prum call_made discovered the first three dimensional photonic crystals made from protein in the ...
Dinamiqs – a Siegfried company
8952 Schlieren, Wagistrasse 25
We are a science-driven contract development and manufacturing organization offering end-to-end viral vector manufacturing solutions. We offer customized services for companies and institutions developing innovative genetic medicines. As a science and technology-driven platform, we provide a comprehensive approach to viral vector manufacturing, from lab-scale development to scalable bioreactor implementation, process optimization, formulation, and stringent quality control.
Dinamiqs – a Siegfried company
Wagistrasse 25
8952 Schlieren
2 Ergebnisse für "discovered" unter Dinamiqs – a Siegfried company
Joe Cox - DINAMIQS
... scientist, Joe later transitioned into the biotech industry where he discovered a passion for technical ... he discovered a passion for technical sales, account management, and business development. Joe is an ...
DINAMIQS welcomes two new leadership team members - DINAMIQS
... transitioning into the biotech industry where he discovered a passion for technical sales, account management ... scientist, later transitioning into the biotech industry where he discovered a passion for technical sales ...
Neurimmune Therapeutics AG
8952 Schlieren, Wagistrasse 18
+41 44 755 46 46
info@neurimmune.com
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.
Neurimmune Therapeutics AG
Wagistrasse 18
8952 Schlieren
10 Ergebnisse für "discovered" unter Neurimmune Therapeutics AG
Neurimmune - Home
... therapeutics. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich ... antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson's disease, the ... therapeutics. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich ... antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson's disease, the ...
Neurimmune - 03.02.2016: BIIB076 (anti-tau mAb) moving into pre-IND...
... monoclonal antibody discovered by Neurimmune has entered into the development stage towards IND. Tau is a ... toxicology studies BIIB076, an anti-tau monoclonal antibody discovered by Neurimmune has entered into the ...
Molecular Partners AG
http://www.molecularpartners.com
8952 Schlieren, Wagistrasse 14
+41 44 755 77 00
Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.
Molecular Partners AG
Wagistrasse 14
8952 Schlieren
5 Ergebnisse für "discovered" unter Molecular Partners AG
Intellectual Property for DARPins - Molecular Partners
... Molecular Partners discovered and initially developed the DARPin base technology at the University of Zurich ... The founders of Molecular Partners discovered and initially developed the DARPin base technology at ...
About Us - Molecular Partners
... discovered DARPins at the University of Zurich, and we continue to bring together talented individuals from ... discovered DARPins at the University of Zurich, and we continue to bring together talented individuals from ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
48 Ergebnisse für "discovered" unter University Hospital Zurich, Research and Education Office
... leukemia formation and the role of a newly- discovered inflammatory phenotype that is closely related to ...
Experimental hematology Lab Prof. Dr. med. Dr. rer. nat. Stefan Bal...
... leukemia formation and the role of a newly- discovered inflammatory phenotype that is closely related to ... - discovered inflammatory phenotype that is closely related to telomere shortening. In collaboration with Prof ...
Repertoire Immune Medicines (Switzerland) AG
8952 Schlieren, Wagistrasse 27
The key to our strategy lies in understanding the inner workings of the immune synapse – the interaction between the T cell and the antigen presenting cell which dictates the immune code that tells a T cell to become toxic and to kill the infected tissue. Our scientists created and developed the DECODETM and DEPLOY suite of technologies, which allows in-depth characterization of TCR-antigen pairings – and the ability to rationally design and clinically develop targeted immune medicines. Our scientists also have developed novel technologies that attach potent immunomodulators to T cells, enabling us to deliver potent cytokines such as IL-15 or IL-12 directly to tumors by using the natural homing power of the T cells to traffic to diseased tissue.
Repertoire Immune Medicines (Switzerland) AG
Wagistrasse 27
8952 Schlieren
4 Ergebnisse für "discovered" unter Repertoire Immune Medicines (Switzerland) AG
Repertoire Immune Medicines Announces Cell Publication Characterizi...
... generated from non-canonical translations of the genome Novel epitopes discovered by Sabeti Lab, Broad ... ™ platform. Through DECODE, researchers discovered the T cells that recognize epitopes in convalescent ... generated from non-canonical translations of the genome Novel epitopes discovered by Sabeti Lab, Broad ... ™ platform. Through DECODE, researchers discovered the T cells that recognize epitopes in convalescent ...
Repertoire Immune Medicines to Present New Data From its DECODE™ Pl...
... novel targets for therapeutic intervention. Repertoire has discovered and validated TCR-antigen pairs ... with a proprietary cytokine payload. In the field of autoimmunity, Repertoire has discovered novel ... develop novel targets for therapeutic intervention. Repertoire has discovered and validated TCR-antigen ... discovered novel immune targets from patients with type 1 diabetes and other autoimmune diseases, providing ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
66 Ergebnisse für "discovered" unter Roche Glycart AG
Collaborators in science
... career to cancer research. After years of arduous work, he discovered that introducing a fluorine atom ... career to cancer research. After years of arduous work, he discovered that introducing a fluorine atom ...
Collaborators in science
... career to cancer research. After years of arduous work, he discovered that introducing a fluorine atom ... career to cancer research. After years of arduous work, he discovered that introducing a fluorine atom ...
Kuros Biosciences AG
8952 Schlieren, Wagistrasse 25
+41 (0)44 733 4747
Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing.
Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
3 Ergebnisse für "discovered" unter Kuros Biosciences AG
Dr. Huipin Yuan - Kuros Biosciences
... worked on biological mechanism of osteoinductive materials in recent years and discovered the role of ... materials in recent years and discovered the role of osteoclastogenesis in material-induced bone formation ...